Structured Exercise after Adjuvant Chemotherapy for Colon Cancer, NEJM (2025) OPTIONS AFTER ACHIEVING WEIGHT-LOSS GOAL ON GLP DRUGS A question I'm often asked is how semaglutide (Wegovy) and tirzepatide (Zepbound) are managed after someone reaches their weight-loss goal
A personalized wellness plan can help address factors that may be contributing to these changes
For patients who wish to undergo cosmetic surgery, weight loss management can decrease the risk of complications during surgery and recovery
Recent GLP-1 Weight Loss Drug Market Developments: Novo Nordisk, Eli Lilly, Amgen, and FDA Lead 20252026 April 2026: Eli Lilly submitted the orforglipron New Drug Application to the FDA for obesity treatment, reporting 14.7% body weight reduction in the ATTAIN-WEIGHT1 Phase 3 trial at the 45mg dose the first oral small molecule GLP-1 receptor agonist NDA submission for dedicated obesity pharmacological treatment in the United States
Because tirzepatide activates two receptors (GLP-1 and GIP) while semaglutide activates one (GLP-1 only), the shape of this dose-response relationship may differ between the medications
